Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16672470 | 0.88 | ALDH1A1 (0.50) | TSHRALDH1A1KMT2ACA12CA7 | |
| SCHEMBL6567525 | 0.86 | MMP8 (0.46) | TSHRALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL16672851 | 0.79 | FFAR1 (0.49) | TSHRALDH1A1KMT2APOLBL3MBTL1 | |
| SCHEMBL19277737 | 0.78 | HCAR2 (0.51) | TSHRALDH1A1KMT2ACA12CA7 | |
| SCHEMBL16672751 | 0.77 | L3MBTL1 (0.41) | KMT2AMEN1L3MBTL1HCAR2FFAR1 | |
| SCHEMBL16014986 | 0.76 | CYP2D6 (0.49) | TSHRALDH1A1L3MBTL1HCAR2FFAR1 | |
| SCHEMBL16672825 | 0.75 | ATM (0.45) | ALDH1A1L3MBTL1HCAR2FFAR1 | |
| SCHEMBL16672677 | 0.75 | CYP2D6 (0.49) | TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL23829513 | 0.75 | NPC1 (0.46) | TSHRALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL3834711 | 0.73 | KMT2A (0.46) | TSHRALDH1A1KMT2AKCNA5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277748-B1 | Process for producing optically active y-Butyrolactone | TAKASAGO PERFUMERY CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1403262-A1 | Process for producing optically active alpha butyrolactone | Takasago International Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | TSHR 4191/4885ALDH1A1 77/4885KMT2A 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.